ID   TRIPC_HUMAN             Reviewed;        1992 AA.
AC   Q14669; D4HL82; Q14CA3; Q14CF1; Q15644; Q53R87; Q53TE7;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   10-MAY-2017, entry version 159.
DE   RecName: Full=E3 ubiquitin-protein ligase TRIP12;
DE            EC=2.3.2.26;
DE   AltName: Full=E3 ubiquitin-protein ligase for Arf;
DE            Short=ULF;
DE   AltName: Full=HECT-type E3 ubiquitin transferase TRIP12;
DE   AltName: Full=Thyroid receptor-interacting protein 12;
DE            Short=TR-interacting protein 12;
DE            Short=TRIP-12;
GN   Name=TRIP12; Synonyms=KIAA0045, ULF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBCELLULAR
RP   LOCATION, INTERACTION WITH MYC AND CDKN2A, AND MUTAGENESIS OF
RP   CYS-1959.
RX   PubMed=20208519; DOI=10.1038/nature08820;
RA   Chen D., Shan J., Zhu W.G., Qin J., Gu W.;
RT   "Transcription-independent ARF regulation in oncogenic stress-mediated
RT   p53 responses.";
RL   Nature 464:624-627(2010).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Bone marrow;
RX   PubMed=7584044; DOI=10.1093/dnares/1.5.223;
RA   Nomura N., Nagase T., Miyajima N., Sazuka T., Tanaka A., Sato S.,
RA   Seki N., Kawarabayasi Y., Ishikawa K., Tabata S.;
RT   "Prediction of the coding sequences of unidentified human genes. II.
RT   The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 1:223-229(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1801-1992.
RX   PubMed=7776974; DOI=10.1210/mend.9.2.7776974;
RA   Lee J.W., Choi H.-S., Gyuris J., Brent R., Moore D.D.;
RT   "Two classes of proteins dependent on either the presence or absence
RT   of thyroid hormone for interaction with the thyroid hormone
RT   receptor.";
RL   Mol. Endocrinol. 9:243-254(1995).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1317, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [7]
RP   FUNCTION.
RX   PubMed=18627766; DOI=10.1016/j.bbrc.2008.07.019;
RA   Park Y., Yoon S.K., Yoon J.B.;
RT   "TRIP12 functions as an E3 ubiquitin ligase of APP-BP1.";
RL   Biochem. Biophys. Res. Commun. 374:294-298(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-310; SER-312; SER-991;
RP   SER-997; SER-1317 AND SER-1322, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   FUNCTION.
RX   PubMed=19028681; DOI=10.1074/jbc.M807554200;
RA   Park Y., Yoon S.K., Yoon J.B.;
RT   "The HECT domain of TRIP12 ubiquitinates substrates of the ubiquitin
RT   fusion degradation pathway.";
RL   J. Biol. Chem. 284:1540-1549(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-312; SER-991; SER-1317
RP   AND SER-1322, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH SMARCC1.
RX   PubMed=20829358; DOI=10.1074/jbc.M110.173997;
RA   Keppler B.R., Archer T.K.;
RT   "Ubiquitin-dependent and ubiquitin-independent control of subunit
RT   stoichiometry in the SWI/SNF complex.";
RL   J. Biol. Chem. 285:35665-35674(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77; SER-312 AND SER-942,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT SER-12; SER-310; SER-1030; SER-1317 AND SER-1322,
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [17]
RP   FUNCTION.
RX   PubMed=22884692; DOI=10.1016/j.cell.2012.06.039;
RA   Gudjonsson T., Altmeyer M., Savic V., Toledo L., Dinant C., Grofte M.,
RA   Bartkova J., Poulsen M., Oka Y., Bekker-Jensen S., Mailand N.,
RA   Neumann B., Heriche J.K., Shearer R., Saunders D., Bartek J.,
RA   Lukas J., Lukas C.;
RT   "TRIP12 and UBR5 Suppress Spreading of Chromatin Ubiquitylation at
RT   Damaged Chromosomes.";
RL   Cell 150:697-709(2012).
RN   [18]
RP   INTERACTION WITH TRADD.
RX   PubMed=22561347; DOI=10.1038/ncb2496;
RA   Chio I.I., Sasaki M., Ghazarian D., Moreno J., Done S., Ueda T.,
RA   Inoue S., Chang Y.L., Chen N.J., Mak T.W.;
RT   "TRADD contributes to tumour suppression by regulating ULF-dependent
RT   p19Arf ubiquitylation.";
RL   Nat. Cell Biol. 14:625-633(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-12; SER-100; SER-312;
RP   SER-942; SER-991 AND SER-997, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1317 AND SER-1322, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase involved in ubiquitin fusion
CC       degradation (UFD) pathway and regulation of DNA repair. Part of
CC       the ubiquitin fusion degradation (UFD) pathway, a process that
CC       mediates ubiquitination of protein at their N-terminus,
CC       regardeless of the presence of lysine residues in target proteins.
CC       In normal cells, mediates ubiquitination and degradation of
CC       isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor
CC       required for p53/TP53 activation under oncogenic stress. In cancer
CC       cells, however, isoform p19ARF/ARF and TRIP12 are located in
CC       different cell compartments, preventing isoform p19ARF/ARF
CC       ubiquitination and degradation. Does not mediate ubiquitination of
CC       isoform p16-INK4a of CDKN2A. Also catalyzes ubiquitination of NAE1
CC       and SMARCE1, leading to their degradation. Ubiquitination and
CC       degradation of target proteins is regulated by interaction with
CC       proteins such as MYC, TRADD or SMARCC1, which disrupt the
CC       interaction between TRIP12 and target proteins. Acts as a key
CC       regulator of DNA damage response by acting as a suppressor of
CC       RNF168, an E3 ubiquitin-protein ligase that promotes accumulation
CC       of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites,
CC       thereby acting as a guard against excessive spreading of
CC       ubiquitinated chromatin at damaged chromosomes.
CC       {ECO:0000269|PubMed:18627766, ECO:0000269|PubMed:19028681,
CC       ECO:0000269|PubMed:20208519, ECO:0000269|PubMed:20829358,
CC       ECO:0000269|PubMed:22884692}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with MYC; leading to disrupt interaction with
CC       isoform p19ARF/ARF of CDKN2A. Interacts with TRADD; leading to
CC       disrupt interaction with isoform p19ARF/ARF of CDKN2A. Interacts
CC       with SMARCC1; leading to disrupt interaction with SMARCE1.
CC       {ECO:0000269|PubMed:20208519, ECO:0000269|PubMed:20829358,
CC       ECO:0000269|PubMed:22561347}.
CC   -!- INTERACTION:
CC       P49286:MTNR1B; NbExp=3; IntAct=EBI-308443, EBI-1188341;
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:20208519}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q14669-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14669-2; Sequence=VSP_044328, VSP_044329;
CC         Note=Ref.1 (ACC99349) sequence is in conflict in position:
CC         380:A->T. {ECO:0000305};
CC       Name=3;
CC         IsoId=Q14669-3; Sequence=VSP_044326, VSP_044328;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q14669-4; Sequence=VSP_044327, VSP_044328, VSP_044329;
CC         Note=No experimental confirmation available.;
CC   -!- SIMILARITY: Belongs to the UPL family. K-HECT subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAY14681.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAY14755.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAA05837.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; EU489742; ACC99349.1; -; mRNA.
DR   EMBL; D28476; BAA05837.2; ALT_INIT; mRNA.
DR   EMBL; AC009973; AAY14755.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC093384; AAY14681.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC105380; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC114556; AAI14557.1; -; mRNA.
DR   EMBL; BC113891; AAI13892.1; -; mRNA.
DR   EMBL; L40383; AAC41731.1; -; mRNA.
DR   CCDS; CCDS33391.1; -. [Q14669-1]
DR   CCDS; CCDS63145.1; -. [Q14669-4]
DR   CCDS; CCDS63146.1; -. [Q14669-3]
DR   RefSeq; NP_001271143.1; NM_001284214.1. [Q14669-3]
DR   RefSeq; NP_001271144.1; NM_001284215.2. [Q14669-2]
DR   RefSeq; NP_001271145.1; NM_001284216.1. [Q14669-4]
DR   RefSeq; NP_001335244.1; NM_001348315.1. [Q14669-3]
DR   RefSeq; NP_001335245.1; NM_001348316.1. [Q14669-2]
DR   RefSeq; NP_004229.1; NM_004238.2. [Q14669-1]
DR   UniGene; Hs.572642; -.
DR   UniGene; Hs.591633; -.
DR   UniGene; Hs.601806; -.
DR   ProteinModelPortal; Q14669; -.
DR   BioGrid; 114731; 53.
DR   DIP; DIP-58584N; -.
DR   IntAct; Q14669; 30.
DR   MINT; MINT-1192877; -.
DR   STRING; 9606.ENSP00000283943; -.
DR   iPTMnet; Q14669; -.
DR   PhosphoSitePlus; Q14669; -.
DR   DMDM; 2499839; -.
DR   EPD; Q14669; -.
DR   MaxQB; Q14669; -.
DR   PaxDb; Q14669; -.
DR   PeptideAtlas; Q14669; -.
DR   PRIDE; Q14669; -.
DR   Ensembl; ENST00000283943; ENSP00000283943; ENSG00000153827. [Q14669-1]
DR   Ensembl; ENST00000389044; ENSP00000373696; ENSG00000153827. [Q14669-3]
DR   Ensembl; ENST00000389045; ENSP00000373697; ENSG00000153827. [Q14669-4]
DR   GeneID; 9320; -.
DR   KEGG; hsa:9320; -.
DR   UCSC; uc002vpw.3; human. [Q14669-1]
DR   CTD; 9320; -.
DR   DisGeNET; 9320; -.
DR   GeneCards; TRIP12; -.
DR   HGNC; HGNC:12306; TRIP12.
DR   HPA; HPA036835; -.
DR   HPA; HPA045893; -.
DR   MIM; 604506; gene.
DR   neXtProt; NX_Q14669; -.
DR   OpenTargets; ENSG00000153827; -.
DR   PharmGKB; PA36985; -.
DR   eggNOG; KOG0168; Eukaryota.
DR   eggNOG; KOG0170; Eukaryota.
DR   eggNOG; COG5021; LUCA.
DR   GeneTree; ENSGT00530000063470; -.
DR   HOGENOM; HOG000007873; -.
DR   HOVERGEN; HBG062085; -.
DR   InParanoid; Q14669; -.
DR   KO; K10590; -.
DR   OMA; VQLMKQX; -.
DR   OrthoDB; EOG091G00GQ; -.
DR   PhylomeDB; Q14669; -.
DR   TreeFam; TF323674; -.
DR   BRENDA; 2.3.2.B9; 2681.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; TRIP12; human.
DR   GeneWiki; TRIP12; -.
DR   GenomeRNAi; 9320; -.
DR   PRO; PR:Q14669; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000153827; -.
DR   CleanEx; HS_TRIP12; -.
DR   ExpressionAtlas; Q14669; baseline and differential.
DR   Genevisible; Q14669; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0046966; F:thyroid hormone receptor binding; IDA:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0009790; P:embryo development; ISS:UniProtKB.
DR   GO; GO:2000780; P:negative regulation of double-strand break repair; IMP:UniProtKB.
DR   GO; GO:1901315; P:negative regulation of histone H2A K63-linked ubiquitination; IMP:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; TAS:Reactome.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   CDD; cd00078; HECTc; 1.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000569; HECT_dom.
DR   InterPro; IPR004170; WWE-dom.
DR   Pfam; PF00632; HECT; 1.
DR   SMART; SM00119; HECTc; 1.
DR   SUPFAM; SSF48371; SSF48371; 2.
DR   SUPFAM; SSF56204; SSF56204; 1.
DR   PROSITE; PS50237; HECT; 1.
DR   PROSITE; PS50918; WWE; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Complete proteome; DNA damage;
KW   DNA repair; Nucleus; Phosphoprotein; Reference proteome; Transferase;
KW   Ubl conjugation pathway.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:21406692}.
FT   CHAIN         2   1992       E3 ubiquitin-protein ligase TRIP12.
FT                                /FTId=PRO_0000173872.
FT   DOMAIN      749    836       WWE. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00248}.
FT   DOMAIN     1885   1992       HECT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00104}.
FT   REGION     1496   1570       K-box.
FT   ACT_SITE   1959   1959       Glycyl thioester intermediate.
FT                                {ECO:0000305}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES      12     12       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      77     77       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES      85     85       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:G5E870}.
FT   MOD_RES     100    100       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     181    181       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:G5E870}.
FT   MOD_RES     310    310       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     312    312       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     942    942       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     991    991       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     997    997       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1016   1016       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:F1LP64}.
FT   MOD_RES    1030   1030       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1317   1317       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1322   1322       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1329   1329       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:G5E870}.
FT   MOD_RES    1376   1376       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:F1LP64}.
FT   MOD_RES    1377   1377       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:F1LP64}.
FT   MOD_RES    1425   1425       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:G5E870}.
FT   MOD_RES    1427   1427       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:G5E870}.
FT   VAR_SEQ      32     32       G -> GRSHLGQAKHKGYSPPESRKSNSKAPKVQSNTTSEL
FT                                SRGHLSK (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_044326.
FT   VAR_SEQ      33    335       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_044327.
FT   VAR_SEQ     380    380       A -> AAASSSV (in isoform 2, isoform 3 and
FT                                isoform 4). {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:20208519}.
FT                                /FTId=VSP_044328.
FT   VAR_SEQ     784    784       E -> EAAHQVGEDEISLSTLGRVYTIDFNSMQ (in
FT                                isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:20208519}.
FT                                /FTId=VSP_044329.
FT   MUTAGEN    1959   1959       C->A: Abolishes E3 ubiquitin-protein
FT                                ligase activity.
FT                                {ECO:0000269|PubMed:20208519}.
FT   CONFLICT   1969   1992       SSIEIMREKLLIAAREGQQSFHLS -> QALRYA (in
FT                                Ref. 5; AAC41731). {ECO:0000305}.
SQ   SEQUENCE   1992 AA;  220434 MW;  294A7C063A3332DE CRC64;
     MSNRPNNNPG GSLRRSQRNT AGAQPQDDSI GGRSCSSSSA VIVPQPEDPD RANTSERQKT
     GQVPKKDNSR GVKRSASPDY NRTNSPSSAK KPKALQHTES PSETNKPHSK SKKRHLDQEQ
     QLKSAQSPST SKAHTRKSGA TGGSRSQKRK RTESSCVKSG SGSESTGAEE RSAKPTKLAS
     KSATSAKAGC STITDSSSAA STSSSSSAVA SASSTVPPGA RVKQGKDQNK ARRSRSASSP
     SPRRSSREKE QSKTGGSSKF DWAARFSPKV SLPKTKLSLP GSSKSETSKP GPSGLQAKLA
     SLRKSTKKRS ESPPAELPSL RRSTRQKTTG SCASTSRRGS GLGKRGAAEA RRQEKMADPE
     SNQEAVNSSA ARTDEAPQGA AGAVGMTTSG ESESDDSEMG RLQALLEARG LPPHLFGPLG
     PRMSQLFHRT IGSGASSKAQ QLLQGLQASD ESQQLQAVIE MCQLLVMGNE ETLGGFPVKS
     VVPALITLLQ MEHNFDIMNH ACRALTYMME ALPRSSAVVV DAIPVFLEKL QVIQCIDVAE
     QALTALEMLS RRHSKAILQA GGLADCLLYL EFFSINAQRN ALAIAANCCQ SITPDEFHFV
     ADSLPLLTQR LTHQDKKSVE STCLCFARLV DNFQHEENLL QQVASKDLLT NVQQLLVVTP
     PILSSGMFIM VVRMFSLMCS NCPTLAVQLM KQNIAETLHF LLCGASNGSC QEQIDLVPRS
     PQELYELTSL ICELMPCLPK EGIFAVDTML KKGNAQNTDG AIWQWRDDRG LWHPYNRIDS
     RIIEQINEDT GTARAIQRKP NPLANSNTSG YSESKKDDAR AQLMKEDPEL AKSFIKTLFG
     VLYEVYSSSA GPAVRHKCLR AILRIIYFAD AELLKDVLKN HAVSSHIASM LSSQDLKIVV
     GALQMAEILM QKLPDIFSVY FRREGVMHQV KHLAESESLL TSPPKACTNG SGSMGSTTSV
     SSGTATAATH AAADLGSPSL QHSRDDSLDL SPQGRLSDVL KRKRLPKRGP RRPKYSPPRD
     DDKVDNQAKS PTTTQSPKSS FLASLNPKTW GRLSTQSNSN NIEPARTAGG SGLARAASKD
     TISNNREKIK GWIKEQAHKF VERYFSSENM DGSNPALNVL QRLCAATEQL NLQVDGGAEC
     LVEIRSIVSE SDVSSFEIQH SGFVKQLLLY LTSKSEKDAV SREIRLKRFL HVFFSSPLPG
     EEPIGRVEPV GNAPLLALVH KMNNCLSQME QFPVKVHDFP SGNGTGGSFS LNRGSQALKF
     FNTHQLKCQL QRHPDCANVK QWKGGPVKID PLALVQAIER YLVVRGYGRV REDDEDSDDD
     GSDEEIDESL AAQFLNSGNV RHRLQFYIGE HLLPYNMTVY QAVRQFSIQA EDERESTDDE
     SNPLGRAGIW TKTHTIWYKP VREDEESNKD CVGGKRGRAQ TAPTKTSPRN AKKHDELWHD
     GVCPSVSNPL EVYLIPTPPE NITFEDPSLD VILLLRVLHA ISRYWYYLYD NAMCKEIIPT
     SEFINSKLTA KANRQLQDPL VIMTGNIPTW LTELGKTCPF FFPFDTRQML FYVTAFDRDR
     AMQRLLDTNP EINQSDSQDS RVAPRLDRKK RTVNREELLK QAESVMQDLG SSRAMLEIQY
     ENEVGTGLGP TLEFYALVSQ ELQRADLGLW RGEEVTLSNP KGSQEGTKYI QNLQGLFALP
     FGRTAKPAHI AKVKMKFRFL GKLMAKAIMD FRLVDLPLGL PFYKWMLRQE TSLTSHDLFD
     IDPVVARSVY HLEDIVRQKK RLEQDKSQTK ESLQYALETL TMNGCSVEDL GLDFTLPGFP
     NIELKKGGKD IPVTIHNLEE YLRLVIFWAL NEGVSRQFDS FRDGFESVFP LSHLQYFYPE
     ELDQLLCGSK ADTWDAKTLM ECCRPDHGYT HDSRAVKFLF EILSSFDNEQ QRLFLQFVTG
     SPRLPVGGFR SLNPPLTIVR KTFESTENPD DFLPSVMTCV NYLKLPDYSS IEIMREKLLI
     AAREGQQSFH LS
//
